Novan ’s loss grew in 2016, but optimistic on development

Novan ’s (Nasdaq: NOVN) net loss grew in 2016, but it remains optimistic on development. The company – which is developing a treatment for acne without the use of antibiotics – reported a net loss of $59.7 million in 2016, up from a net loss of $28.1 million the year prior. Novan said in an announ cement of its fourth quarter and full-year results Monday that its research and development expenses increased from $16.6 million in 2015 to $46.5 million in 2016 “due primarily to increased development…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news